257 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28363748	8	Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives.	Takeda Pharmaceutical
28051871	100	Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.	Instituto De Qu£Mica M£Dica (Iqm-Csic)
27836399	26	[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.	Bristol-Myers Squibb Research and Development
27810243	87	Discovery of indazole ethers as novel, potent, non-steroidal glucocorticoid receptor modulators.	Astrazeneca
27994732	56	Development of	Tokyo Medical and Dental University
27994731	3	Identification of Triptophenolide from	Chinese Academy of Medical Science
27717544	75	Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.	Integral Biosciences
27665178	42	Development of 6-arylcoumarins as nonsteroidal progesterone antagonists. Structure-activity relationships and fluorescence properties.	Ochanomizu University
27301368	4	Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.	Cardiff University
26819671	51	Optimizing Ligand Efficiency of Selective Androgen Receptor Modulators (SARMs).	Glaxosmithkline
26965862	3	7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.	Cardiff University
26683992	25	2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile: A Transdermal Selective Androgen Receptor Modulator (SARM) for Muscle Atrophy.	Eli Lilly
26407012	80	Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.	Astrazeneca
26295173	25	Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.	Ochanomizu University
26288692	37	Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.	Bristol-Myers Squibb Research and Development
26305181	13	Discovery of Potent 17ß-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.	University of Arizona
26218343	76	Indole Glucocorticoid Receptor Antagonists Active in a Model of Dyslipidemia Act via a Unique Association with an Agonist Binding Site.	Eli Lilly
26046313	20	Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.	Alla Chem
25978072	53	Synthesis and Biological Evaluation of Cyclopentaquinoline Derivatives as Nonsteroidal Glucocorticoid Receptor Antagonists.	TBA
25879485	60	Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.	Seragon Pharmaceuticals
25941555	75	Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.	Merck Research Laboratories
25706100	65	2-Aryl-3-methyloctahydrophenanthrene-2,3,7-triols as potent dissociated glucocorticoid receptor agonists.	TBA
25591066	23	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.	University of Maryland
25646649	20	Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.	University of Gothenburg
25862209	31	Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I.	Takeda Pharmaceutical
25121964	18	3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration.	Novartis Institutes For Biomedical Research
25025737	37	Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).	University of British Columbia
24980053	153	Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.	Bristol-Myers Squibb
25440884	2	Synthetic derivatives of aromatic abietane diterpenoids and their biological activities.	Universidad De Valencia
25305688	41	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t.	Phenex Pharmaceuticals
25187277	136	Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.	Takeda Pharmaceutical
24755427	107	The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation.	Astrazeneca
24738581	81	Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.	Pfizer
24726305	3	Preliminary investigations into triazole derived androgen receptor antagonists.	Deakin University
24630411	38	Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.	Merck Research Laboratories
24527807	82	1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators.	Pfizer
24446728	30	Glucocorticoid receptor modulators informed by crystallography lead to a new rationale for receptor selectivity, function, and implications for structure-based design.	Eli Lilly
24157365	23	Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.	Pfizer
24900588	25	Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists.	Tokyo Medical and Dental University
24044500	2	Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.	National Cancer Institute-Frederick
23953070	146	Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists.	Ironwood Pharmaceuticals
23916594	92	Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists.	Bristol-Myers Squibb
23958516	61	Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists.	Takeda Pharmaceutical
23777778	101	Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.	Merck Research Laboratories
23768907	6	Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERa-selective antagonist.	The University of Tokyo
23727044	6	Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.	Korea Research Institute of Chemical Technology
23713567	13	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.	University of Maryland
23611768	34	The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity.	Meijo University
23466225	2	Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.	Astrazeneca
23462715	25	Development of silicon-containing bis-phenol derivatives as androgen receptor antagonists: selectivity switching by C/Si exchange.	The University of Tokyo
23199477	47	Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists.	Takeda Pharmaceutical
23432095	160	Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17ß-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.	Vanderbilt University School of Medicine
23301637	63	Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.	University of British Columbia
22280402	12	"True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.	Trinity College
20727743	64	Discovery of quinolines as selective glucocorticoid receptor agonists.	Bayer Schering Pharma
20469868	176	Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists.	Glaxosmithkline
19856921	21	Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.	Acadia Pharmaceuticals
19664922	35	2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists.	Glaxosmithkline
18952422	5	The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist.	Glaxosmithkline
11150172	8	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.	Schering
23079530	27	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.	Pfizer
22897611	2	Discovery of diarylhydantoins as new selective androgen receptor modulators.	Galapagos, Parc Biocitech
22866979	19	Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.	Pfizer
22746350	41	Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[d]isoxazole-containing androgen receptor modulators.	University of Eastern Finland
22507964	17	Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.	Perelman School of Medicine University of Pennsylvania
22377517	15	Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.	Pfizer
22310230	2	Methoxychalcone inhibitors of androgen receptor translocation and function.	National Cancer Institute-Bethesda
21073190	135	Dimethyl-diphenyl-propanamide Derivatives As Nonsteroidal Dissociated Glucocorticoid Receptor Agonists.	Bristol-Myers Squibb
21050768	20	Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.	Chugai Pharmaceutical
21036041	22	Synthesis of potent, substituted carbazoles as selective androgen receptor modulators (SARMs).	Radius Health
20888766	50	Novel selective anti-androgens with a diphenylpentane skeleton.	The University of Tokyo
20672822	108	Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.	Pfizer
20672820	92	Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.	Pfizer
20638844	25	1-Methyl-1H-pyrrole-2-carbonitrile containing tetrahydronaphthalene derivatives as non-steroidal progesterone receptor antagonists.	Pfizer
20584610	90	Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.	Bristol-Myers Squibb
20510622	142	Aromatic beta-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists.	Chinese Academy of Sciences
20381361	43	Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists.	Chugai Pharmaceutical
20355713	3	Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget.	University of Illinois
19863083	25	The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144.	Wyeth Research
20047280	174	Novel synthesis of the hexahydroimidazo[1,5b]isoquinoline scaffold: application to the synthesis of glucocorticoid receptor modulators.	Bristol-Myers Squibb
19321341	101	Discovery of novel dihydro-9,10-ethano-anthracene carboxamides as glucocorticoid receptor modulators.	Bristol-Myers Squibb
18722119	55	1,5-Dihydro-benzo[e][1,4]oxazepin-2(1H)-ones containing a 7-(5'-cyanopyrrol-2-yl) group as nonsteroidal progesterone receptor modulators.	Wyeth Research
18504132	51	7-aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists.	Wyeth Research
18400499	53	Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.	Ligand Pharmaceuticals
18513967	103	Discovery of nonsteroidal glucocorticoid receptor ligands based on 6-indole-1,2,3,4-tetrahydroquinolines.	Ligand Pharmaceuticals
18032610	4	Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.	Ligand Pharmaceuticals
17911242	1	A surface on the androgen receptor that allosterically regulates coactivator binding.	University of California
17606915	4	Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.	The Scripps Research Institute
18318463	53	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).	Wyeth Research
18442912	90	Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.	Ligand Pharmaceuticals
18291644	62	Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.	Bristol-Myers Squibb Pharmaceutical Research and Development
17890084	86	Androstene-3,5-dienes as ER-beta selective SERMs.	Merck Research Laboratories
17448656	80	Bridged androstenediol analogs as ER-beta selective SERMs.	Merck Research Laboratories
17064916	61	Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships.	Chugai Pharmaceutical
16309907	129	Androstenediol analogs as ER-beta-selective SERMs.	Merck Research Laboratories
16250653	22	Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study.	Universit£
15771445	22	Binding thermodynamics as a tool to investigate the mechanisms of drug-receptor interactions: thermodynamics of cytoplasmic steroid/nuclear receptors in comparison with membrane receptors.	University of Ferrara
15456242	30	11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor.	The Pennsylvania State University
15293993	172	Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes.	Abbott Laboratories
14613328	10	Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate.	University of Colorado
12238914	48	6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists.	Women'S Health Research Institute
12036351	31	Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists.	Pfizer
10212133	93	5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification.	Ligand Pharmaceuticals
9925725	9	Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071).	Ligand Pharmaceuticals
9484511	111	Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.	Ligand Pharmaceuticals
8627601	169	Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.	Ligand Pharmaceuticals
15081005	30	Novel pyrrole-containing progesterone receptor modulators.	Wyeth Research
15080982	122	Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists.	Abbott Laboratories
12781198	108	Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.	Ligand Pharmaceuticals
12781197	59	Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators.	Ligand Pharmaceuticals
10743938	103	Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.	Ligand Pharmaceuticals
10340624	72	4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.	Ligand Pharmaceuticals
9873735	111	5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.	Ligand Pharmaceuticals
22391033	69	Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.	Takeda Pharmaceutical
22197140	15	Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.	Pfizer
22094279	75	Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.	Takeda Pharmaceutical
22074142	89	Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.	Takeda Pharmaceutical
22047606	29	Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.	University of British Columbia
21936524	21	Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.	Pfizer
21899328	244	Azaxanthene based selective glucocorticoid receptor modulators: design, synthesis, and pharmacological evaluation of (S)-4-(5-(1-((1,3,4-thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and its methylene homologue (BMS-791	Bristol-Myers Squibb
21916484	41	6-arylcoumarins as novel nonsteroidal type progesterone antagonists: an example with receptor-binding-dependent fluorescence.	Ochanomizu University
21831636	75	Pantolactams as androgen receptor antagonists for the topical suppression of sebum production.	Pfizer
21846139	12	Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening.	University of British Columbia
21506597	6	Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets.	The University of Tennessee
21324689	74	Nonsteroidal 2,3-dihydroquinoline glucocorticoid receptor agonists with reduced PEPCK activation.	Ligand Pharmaceuticals
21316964	108	Discovery of orally available tetrahydroquinoline-based glucocorticoid receptor agonists.	Ligand Pharmaceuticals
24900290	7	Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140	TBA
24900294	72	Novel 3-Aryl Indoles as Progesterone Receptor Antagonists for Uterine Fibroids	TBA
21115247	64	Tetrahydroquinoline glucocorticoid receptor agonists: discovery of a 3-hydroxyl for improving receptor selectivity.	Ligand Pharmaceuticals
20826091	6	20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.	UniversitäT Leipzig
20813948	63	Spiroindolones, a potent compound class for the treatment of malaria.	Swiss Tropical and Public Health Institute
20638278	145	Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.	Phenex Pharmaceuticals
20462217	17	Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery.	Pfizer
20430618	21	Optimisation of a pyrazole series of progesterone antagonists; Part 1.	Pfizer
20408553	27	Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.	Pfizer
20226658	5	Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay.	Meijo University
20144545	19	LXXLL peptide mimetics as inhibitors of the interaction of vitamin D receptor with coactivators.	The University of Tokyo
19954971	40	Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.	Sumitomo Chemical
19616429	32	Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists.	Glaxosmithkline
19595590	49	Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.	Glaxosmithkline
19606870	53	Design, synthesis, and biological evaluation of 16-substituted 4-azasteroids as tissue-selective androgen receptor modulators (SARMs).	Merck Research Laboratories
19592245	11	Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.	Meijo University
19432422	16	Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.	Gtx
19286380	49	Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production.	Pfizer
19239259	66	Octahydrophenanthrene-2,7-diol analogues as dissociated glucocorticoid receptor agonists: discovery and lead exploration.	Pfizer
19201190	56	4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production.	Pfizer
18707892	2	Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring.	Tohoku Pharmaceutical University
18571420	71	4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor.	The University of Tokyo
18553958	28	A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.	Ligand Pharmaceuticals
18038968	26	(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.	Eli Lilly
17827000	6	(1R,2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production.	Pfizer
17804229	31	Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists.	Chugai Pharmaceutical
17766112	22	Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production.	Pfizer
17764935	32	Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production.	Pfizer
17703938	55	Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.	Ligand Pharmaceuticals
17681796	21	5-(3-Cyclopentyl-2-thioxo-2,3-dihydro-1H-benzimidazol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile: A novel, highly potent, selective, and orally active non-steroidal progesterone receptor agonist.	Wyeth Research
17574413	24	Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.	Bristol-Myers Squibb Research and Development
17553679	148	5(Z)-benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulators.	Ligand Pharmaceuticals
17292608	48	Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators.	Pharmaceutical Research Institute
17197181	3	Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-Trifluoroethyl-benzimidazole scaffold.	Johnson & Johnson Pharmaceutical Research and Development
17149866	4	Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist.	Orebro University
16019211	14	Ligands with dual vitamin D3-agonistic and androgen-antagonistic activities.	The University of Tokyo
15603960	84	Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.	Bristol-Myers Squibb Pharmaceutical Research Institute
15603938	54	Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.	Bristol-Myers Squibb Pharmaceutical Research Institute
15546739	60	The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists.	Bristol-Myers Squibb Pharmaceutical Research Institute
15509168	10	Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.	University of Colorado
15081010	66	Discovery of novel nonsteroidal glucocorticoid receptor modulators.	Abbott Laboratories
12954062	140	5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.	Ligand Pharmaceuticals
12873487	5	Anti-androgens with full antagonistic activity toward human prostate tumor LNCaP cells with mutated androgen receptor.	The University of Tokyo
12620078	132	Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines.	Abbott Laboratories
11520196	81	Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity.	Abbott Laboratories
32847363	66	Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.	Gifu Pharmaceutical University
11356108	3	Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands.	The University of Tennessee Health Science Center
27503683	12	Non-canonical modulators of nuclear receptors.	Vitae Pharmaceuticals
27437082	12	Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3?-Imidazole Carbamate.	University of Maryland
27563404	36	Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer.	University of Pittsburgh
10743937	66	Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.	Ligand Pharmaceuticals
30525603	162	New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.	University of Tennessee Health Science Center
31274313	95	Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).	Oric Pharmaceuticals
31940200	62	Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.	Genomics Institute of The Novartis Research Foundation (Gnf)
10230629	69	Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.	Ligand Pharmaceuticals
10230628	95	Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one.	Ligand Pharmaceuticals
29400967	136	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.	Bristol-Myers Squibb
31185168	144	Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.	Rti International
9871534	95	New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.	Ligand Pharmaceuticals
31271960	1	Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.	The Czech Academy of Sciences
9784110	81	5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.	Ligand Pharmaceuticals
30925341	4	Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.	Sichuan University and Collaborative Innovation Center For Biotherapy
9464360	145	5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.	Ligand Pharmaceuticals
26568144	8	Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.	Eli Lilly
25062331	81	Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.	University of British Columbia
30193215	20	Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.	Vancouver Prostate Centre (Vpc)
30189396	38	5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.	Kanazawa University
30144697	66	Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-? agonists (SERBAs).	Marquette University
28594553	10	Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.	National Institute of Health Sciences
29424542	138	Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile.	Astrazeneca
30091920	113	Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).	Oric Pharmaceuticals
30034593	58	Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.	The University of Tokyo
29407970	1	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex.	Nanjing Forestry University
29117897	3	Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.	China Pharmaceutical University
28757062	6	Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5?-androst-17?-amide derivatives as dual 5?-reductase inhibitors and androgen receptor antagonists.	China Pharmaceutical University
28043796	84	Discovery of new selective glucocorticoid receptor agonist leads.	Bayer Pharma
28696695	77	Structure-Based Approach To Identify 5-[4-Hydroxyphenyl]pyrrole-2-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators.	Pfizer
29300474	45	Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.	Pfizer
28478926	2	Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles.	Chinese Academy of Sciences
28454849	48	Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.	Takeda Pharmaceutical
28385503	19	Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer.	Drexel University College of Medicine
26878082	196	An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.	University of Bonn
28411406	16	Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors	China Pharmaceutical University
12237342	2	High affinity antagonists of the vanilloid receptor.	National Cancer Institute-Bethesda
8935801	586	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.	Janssen Research Foundation
16216042	10	Synthesis and biological evaluation of novel EG5 inhibitors.	University of Leipzig
1840645	85	Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.	University of Toronto
16990005	11	Identification of 2-arylbenzimidazoles as potent human histamine H4 receptor ligands.	Johnson & Johnson Pharmaceutical
15013001	10	Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.	Glaxosmithkline